{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T06:39:43Z","timestamp":1789799983998,"version":"4.0.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,9,16]],"date-time":"2012-09-16T00:00:00Z","timestamp":1347753600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1471-2474-13-174","type":"journal-article","created":{"date-parts":[[2012,9,16]],"date-time":"2012-09-16T00:14:11Z","timestamp":1347754451000},"source":"Crossref","is-referenced-by-count":37,"title":["Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout"],"prefix":"10.1186","volume":"13","author":[{"given":"Nicola","family":"Dalbeth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meaghan E","family":"House","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Horne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith J","family":"Petrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona M","family":"McQueen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,16]]},"reference":[{"issue":"2","key":"1475_CR1","first-page":"9","volume":"48","author":"F Perez-Ruiz","year":"2009","unstructured":"Perez-Ruiz F: Treating to target: a strategy to cure gout. Rheumatology (Oxford). 2009, 48 (2): 9-14.","journal-title":"Rheumatology (Oxford)"},{"key":"1475_CR2","first-page":"577","volume":"28","author":"J Li-Yu","year":"2001","unstructured":"Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E, Schumacher HR: Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?. J Rheumatol. 2001, 28: 577-580.","journal-title":"J Rheumatol"},{"key":"1475_CR3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/art.20405","volume":"51","author":"A Shoji","year":"2004","unstructured":"Shoji A, Yamanaka H, Kamatani N: A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004, 51: 321-325. 10.1002\/art.20405.","journal-title":"Arthritis Rheum"},{"key":"1475_CR4","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/art.10511","volume":"47","author":"F Perez-Ruiz","year":"2002","unstructured":"Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A: Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002, 47: 356-360. 10.1002\/art.10511.","journal-title":"Arthritis Rheum"},{"key":"1475_CR5","first-page":"1888","volume":"34","author":"F Perez-Ruiz","year":"2007","unstructured":"Perez-Ruiz F, Martin I, Canteli B: Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol. 2007, 34: 1888-1893.","journal-title":"J Rheumatol"},{"key":"1475_CR6","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","volume":"46","author":"KM Jordan","year":"2007","unstructured":"Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, Hingorani A, Jaques R, Nuki G: British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford). 2007, 46: 1372-1374. 10.1093\/rheumatology\/kem056a.","journal-title":"Rheumatology (Oxford)"},{"key":"1475_CR7","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentao J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gorska I: EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006, 65: 1312-1324. 10.1136\/ard.2006.055269.","journal-title":"Ann Rheum Dis"},{"key":"1475_CR8","first-page":"1646","volume":"33","author":"N Dalbeth","year":"2006","unstructured":"Dalbeth N, Kumar S, Stamp L, Gow P: Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006, 33: 1646-1650.","journal-title":"J Rheumatol"},{"key":"1475_CR9","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1136\/ard.2007.070755","volume":"66","author":"E Roddy","year":"2007","unstructured":"Roddy E, Zhang W, Doherty M: Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis. 2007, 66: 1311-1315. 10.1136\/ard.2007.070755.","journal-title":"Ann Rheum Dis"},{"key":"1475_CR10","doi-asserted-by":"publisher","first-page":"R46","DOI":"10.1186\/ar2659","volume":"11","author":"LR Harrold","year":"2009","unstructured":"Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, Ockene IS: Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther. 2009, 11: R46-10.1186\/ar2659.","journal-title":"Arthritis Res Ther"},{"key":"1475_CR11","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/rheumatology\/keh679","volume":"44","author":"TR Mikuls","year":"2005","unstructured":"Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG: Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford). 2005, 44: 1038-1042. 10.1093\/rheumatology\/keh679.","journal-title":"Rheumatology (Oxford)"},{"key":"1475_CR12","volume-title":"Why is Management Suboptimal and What Can Be Done About It?","author":"NL Edwards","year":"2010","unstructured":"Edwards NL, Quality of Care in Patients with Gout: Why is Management Suboptimal and What Can Be Done About It?. 2010, Curr Rheumatol Rep: Curr Rheumatol Rep"},{"key":"1475_CR13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1177\/1742395310378761","volume":"6","author":"LR Harrold","year":"2010","unstructured":"Harrold LR, Mazor KM, Velten S, Ockene IS, Yood RA: Patients and providers view gout differently: a qualitative study. Chronic Illn. 2010, 6: 263-271. 10.1177\/1742395310378761.","journal-title":"Chronic Illn"},{"key":"1475_CR14","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1136\/ard.2007.076182","volume":"67","author":"DH Solomon","year":"2008","unstructured":"Solomon DH, Avorn J, Levin R, Brookhart MA: Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis. 2008, 67: 609-613.","journal-title":"Ann Rheum Dis"},{"key":"1475_CR15","first-page":"43","volume":"121","author":"R Suppiah","year":"2008","unstructured":"Suppiah R, Dissanayake A, Dalbeth N: High prevalence of gout in patients with Type 2 diabetes: male sex, renal impairment, and diuretic use are major risk factors. N Z Med J. 2008, 121: 43-50.","journal-title":"N Z Med J"},{"key":"1475_CR16","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/art.1780200320","volume":"20","author":"SL Wallace","year":"1977","unstructured":"Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF: Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977, 20: 895-900. 10.1002\/art.1780200320.","journal-title":"Arthritis Rheum"},{"key":"1475_CR17","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/acr.20570","volume":"63","author":"N Dalbeth","year":"2011","unstructured":"Dalbeth N, Petrie KJ, House M, Chong J, Leung W, Chegudi R, Horne A, Gamble G, McQueen FM, Taylor WJ: Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability. Arthritis Care Res (Hoboken). 2011, 63: 1605-1612. 10.1002\/acr.20570.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1475_CR18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1023\/A:1025508928696","volume":"20","author":"F Talbot","year":"1997","unstructured":"Talbot F, Nouwen A, Gingras J, Gosselin M, Audet J: The assessment of diabetes-related cognitive and social factors: the Multidimensional Diabetes Questionnaire. J Behav Med. 1997, 20: 291-312. 10.1023\/A:1025508928696.","journal-title":"J Behav Med"},{"key":"1475_CR19","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/art.30119","volume":"63","author":"LK Stamp","year":"2011","unstructured":"Stamp LK, O'Donnell JL, Zhang M, James J, Frampton C, Barclay ML, Chapman PT: Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011, 63: 412-421. 10.1002\/art.30119.","journal-title":"Arthritis Rheum"},{"key":"1475_CR20","volume-title":"Ann Rheum Dis","author":"K Spencer","year":"2012","unstructured":"Spencer K, Carr A, Doherty M: Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis. 2012"},{"key":"1475_CR21","volume-title":"Ann Rheum Dis","author":"F Rees","year":"2012","unstructured":"Rees F, Jenkins W, Doherty M: Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2012"},{"key":"1475_CR22","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1136\/bmj.e191","volume":"344","author":"P Chandratre","year":"2012","unstructured":"Chandratre P, Roddy E, Mallen C: Patient related factors are also important in treating gout. BMJ. 2012, 344: e191-10.1136\/bmj.e191.","journal-title":"BMJ"},{"key":"1475_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11926-011-0228-0","volume":"14","author":"N Dalbeth","year":"2012","unstructured":"Dalbeth N, Lindsay K: The patient's experience of gout: new insights to optimize management. Curr Rheumatol Rep. 2012, 14: 173-178. 10.1007\/s11926-011-0228-0.","journal-title":"Curr Rheumatol Rep"},{"key":"1475_CR24","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jbspin.2011.05.010","volume":"78","author":"G Reach","year":"2011","unstructured":"Reach G: Treatment adherence in patients with gout. Joint Bone Spine. 2011, 78: 456-459. 10.1016\/j.jbspin.2011.05.010.","journal-title":"Joint Bone Spine"},{"key":"1475_CR25","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1002\/art.30520","volume":"63","author":"Y Zhu","year":"2011","unstructured":"Zhu Y, Pandya BJ, Choi HK: Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007\u20132008. Arthritis Rheum. 2011, 63: 3136-3141. 10.1002\/art.30520.","journal-title":"Arthritis Rheum"},{"key":"1475_CR26","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0140-6736(66)91320-1","volume":"1","author":"IA Prior","year":"1966","unstructured":"Prior IA, Rose BS, Harvey HP, Davidson F: Hyperuricaemia, gout, and diabetic abnormality in Polynesian people. Lancet. 1966, 1: 333-338.","journal-title":"Lancet"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-13-174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2474-13-174\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-13-174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,7,13]],"date-time":"2016-07-13T04:14:23Z","timestamp":1468383263000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/1471-2474-13-174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,16]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["1475"],"URL":"https:\/\/doi.org\/10.1186\/1471-2474-13-174","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,16]]},"article-number":"174"}}